🇩🇰 Medical cannabis in Denmark

B — controlled national programme. Cannabis is a distinct legal category ('Lov om ordning med medicinsk cannabis'), embedded in the public system: listed intermediate products, pharmacy preparation, e-prescription in the national medication record.

The pilot scheme (forsøgsordning) ran from 1 January 2018 and was made permanent by Lov nr. 439 af 6. maj 2025, which renamed the parent law 'Lov om ordning med medicinsk cannabis' (Act on the medical cannabis scheme) and entered into force on 1 January 2026 (§ 3). Products are 'ikke godkendte lægemidler' (not authorised medicines). Separately, authorised medicines (Sativex, Epidyolex), imported dronabinol/nabilone under individual permits and magistral preparations exist outside the scheme.

Source: Lægemiddelstyrelsen — Ordningen med medicinsk cannabis · read 27 September 2026

Dried flower and oral oils from the official list (15 intermediate products as of June 2026), which the pharmacy turns into a final product for you; plus Sativex and Epidyolex (neurologists only), magistral preparations, and imported dronabinol/nabilone on a case-by-case permit.

Lægemiddelstyrelsen's 'Liste over optagne cannabismellemprodukter' (list of admitted cannabis intermediate products, updated 22 June 2026) holds 15 products: dried flower (Bedrocan, Bediol, Bedica, Bedrobinol, Bedrolite from the Netherlands, distributed by CannGros/Scanleaf) and oral solutions (Stenocare, Scanleaf THC/CBD oils). Under § 17 of the Act, a pharmacy or hospital pharmacy may only prepare a 'cannabisslutprodukt' (final product) from an intermediate product on the list. Inclusion on the list does not guarantee availability; medicinpriser.dk marks several products as discontinued in 2026.

Source: Lægemiddelstyrelsen — Liste over optagne cannabismellemprodukter · read 27 September 2026

Any licensed doctor in Denmark may prescribe scheme products ('fri ordinationsret'), but none is obliged to; Sativex and Epidyolex are restricted to neurologists.

Lægemiddelstyrelsen: 'Alle læger har mulighed for at udskrive de produkter, der er optaget i ordning om medicinsk cannabis, men ingen læge er forpligtet til det.' The agency recommends use only after authorised medicines have failed, names five indications where evidence is considered supportive (neuropathic pain, cancer pain, MS pain/spasticity, spinal cord injury pain, chemotherapy nausea) and strongly advises against prescribing to under-18s. The doctor carries full responsibility for dosing and follow-up.

Source: Lægemiddelstyrelsen — Spørgsmål og svar om medicinsk cannabis · read 27 September 2026

Electronic prescription in the national Fælles Medicinkort (shared medication record), tied to your CPR number; maximum one month's supply per prescription, dispensed once.

VEJ nr. 9548 af 24/06/2024 (Guidance on doctors' treatment of patients with medical cannabis): 'recepten skal udstedes elektronisk i det fælles medicinkort'; the prescription must include the patient's name, address and CPR number, product, strength, indication and dosage. 'En læge må maksimalt ordinere til en måneds forbrug på en recept' and 'Apoteket må kun udlevere én gang efter samme recept.'

Source: VEJ nr. 9548 af 24/06/2024 — Vejledning om lægers behandling af patienter med medicinsk cannabis (retsinformation) · read 27 September 2026

No published rule requires an in-person visit before a cannabis prescription; the doctor must issue the e-prescription in the national medication record, which requires a Danish CPR number.

The official guidance (VEJ nr. 9548/2024) contains no provision on video or remote consultations for medical cannabis; it requires electronic prescribing in Fælles Medicinkort and recommends follow-up on effect and safety. Whether a specific clinic starts treatment by video is a matter of the doctor's own clinical judgement under general Danish rules; no cannabis-specific telemedicine restriction was found on regulator pages.

Source: VEJ nr. 9548 af 24/06/2024 (retsinformation) · read 27 September 2026

Community and hospital pharmacies prepare the final product from a listed intermediate product and may only hand it out from the preparing pharmacy; medicines with euphoriant substances may never be received by post from abroad.

Lov nr. 439/2025 § 17 stk. 1: 'Et apotek og et sygehusapotek må kun fremstille et cannabisslutprodukt ud fra et cannabismellemprodukt optaget på Lægemiddelstyrelsens liste', and final products are dispensed only from the pharmacy that prepared them. The pharmacy must check the prescription and inform the patient of cheaper equivalents (VEJ 9548/2024). Domestic home delivery by Danish pharmacies was not addressed on the pages opened.

Source: LOV nr. 439 af 06/05/2025 — Lov om ændring af lov om forsøgsordning med medicinsk cannabis (retsinformation) · read 27 September 2026

The public system covers 50% of your spending on scheme products up to DKK 20,000 per year (max DKK 10,000 subsidy); terminally ill patients get 100%.

Lægemiddelstyrelsen Q&A: '50% tilskud til udgifter op til 20.000 kr., det vil sige op til 10.000 kr. i tilskud om året'; terminal patients receive 100% coverage. For cannabis medicines outside the scheme (magistral, imported) individual subsidy (enkelttilskud) can be applied for. The political agreement of 28 November 2024 (Indenrigs- og Sundhedsministeriet) continues the scheme's arrangements from 2026.

Source: Lægemiddelstyrelsen — Spørgsmål og svar om medicinsk cannabis · read 27 September 2026

Official pharmacy prices are published fortnightly on medicinpriser.dk (Lægemiddelstyrelsen), category 'Cannabisprodukt'; no fixed public price list is stated elsewhere.

medicinpriser.dk, run by Lægemiddelstyrelsen, lists 14–15 cannabis products for the price period 14.09.2026–27.09.2026 with several marked discontinued (e.g. Bediol 'Scanleaf', Bedrobinol 'CannGros', CBD20 'Stenocare' as of 31.08.2026). Individual prices were not readable in this session and are not reproduced here.

Source: medicinpriser.dk — Cannabisprodukt (Lægemiddelstyrelsen) · read 27 September 2026

Denmark has a zero THC limit (0.001 mg/kg blood) for drivers, but it does not apply to a medicine taken according to a lawful prescription; impairment remains an offence, and the Patient Safety Authority recommends doctors issue a medical driving ban for the whole cannabis treatment.

Færdselsloven § 54 stk. 1 nr. 2 sets a zero limit (0.001 mg THC/kg blood). The Director of Public Prosecutions' circular (Rigsadvokatmeddelelsen, CIR1H nr. 9171 af 27/03/2020) quotes the exception: 'Bestemmelserne i § 54, stk. 1, nr. 1 og 2, finder ikke anvendelse for stoffer, som den pågældende har indtaget i henhold til og i overensstemmelse med en lovlig recept'. Lægemiddelstyrelsen's Q&A states that Styrelsen for Patientsikkerhed (Danish Patient Safety Authority) 'anbefaler aktuelt at læger ... udsteder lægeligt kørselsforbud i hele behandlingstiden', and VEJ 9548/2024 requires doctors to assess each patient's fitness to drive.

Source: Rigsadvokatmeddelelsen — Kørsel under påvirkning af bevidsthedspåvirkende stoffer (færdselslovens § 54) (retsinformation) · read 27 September 2026

Within Schengen, ask your pharmacy for a 'pillepas' (Schengen certificate) before travelling; you may bring medicine with euphoriant substances, including medical cannabis, into Denmark only in person and for at most 30 days' treatment, never by post.

Lægemiddelstyrelsen's rules on medicine brought in from abroad (valid from 1 January 2026, based on Bekendtgørelse om privatpersoners indførsel af lægemidler til mennesker og dyr, BEK 2025/1523): euphoriant substances from EU/EEA — in person only, max 30 days' treatment; from non-EU/EEA countries — in person only, max 30 days, with documentation; 'Du må aldrig modtage medicin med euforiserende stoffer med posten'. Cannabis for medical use is listed among euphoriant substances. For travel within Schengen the pillepas (Schengen-attest, Art. 75 Schengen Convention) is issued by Danish pharmacies.

Source: Lægemiddelstyrelsen — Medicin indført fra udlandet · read 27 September 2026

There is no legal bar on treating non-residents, but the prescription must be issued electronically in the Danish medication record against a CPR number, which visitors normally lack. An EU/EEA paper prescription can in principle be dispensed in Denmark, but whether this covers cannabis products (euphoriant substances) is not stated on the official page; bringing your own supply is limited to 30 days, in person.

(1) Non-residents: no residency condition appears in the Act or VEJ 9548/2024, but the e-prescription in Fælles Medicinkort requires name, address and CPR number; how a visitor without CPR would be prescribed is not published. (2) Foreign EU/EEA prescriptions: Denmark transposed Directive 2011/24/EU Art. 11 in Receptbekendtgørelsen (BEK nr. 857 af 12. juni 2020) § 70 and bilag 4; Lægemiddelstyrelsen's page 'Recepter fra andet land' lists the required content and notes that cross-border e-prescribing is not yet possible. The page does not say whether prescriptions for euphoriant substances or scheme cannabis products are excluded (Art. 11(6)); the regulation text itself could not be opened in this session — 'not published' on the page opened. (3) Bringing medicine in: Schengen residents use the Art. 75 certificate; all travellers may carry euphoriant medicines only in person, max 30 days, non-EU with documentation, never by post. (4) Foreign telemedicine prescriptions: no official statement; a cannabis final product is made by a Danish pharmacy against a Danish e-prescription, so a foreign e-prescription cannot currently be transmitted (no cross-border e-prescribing per Lægemiddelstyrelsen).

Source: Lægemiddelstyrelsen — Recepter fra andet land · read 27 September 2026

The scheme became permanent on 1 January 2026; a new regulation on intermediate products (BEK nr. 1608/2025) applies from the same date. No further pending change was found.

Lov nr. 439 af 6. maj 2025 made the scheme permanent and renamed the Act from 1 January 2026. Bekendtgørelse om cannabismellemprodukter (BEK nr. 1608 af 05/12/2025) entered into force 1 January 2026. The November 2024 political agreement also promised better guidance for doctors and patients and a better framework for producers (pesticides, export); implementation of those points was not verified.

Source: LOV nr. 439 af 06/05/2025 (retsinformation) · read 27 September 2026

About 1,800 patients a year were on scheme products in 2024 (ministry, Nov 2024); in 2025 patients rose 54% and redeemed prescriptions 64% on 2024. Safety monitoring over the same year: 3 suspected adverse-reaction reports, as in 2024 and 2023 — the regulator identified no safety signal for cannabis final products.

Lægemiddelstyrelsen, news of 11.09.2026 ('Indberettede formodede bivirkninger ved medicinsk cannabis under forsøgsordningen i 2025'): 3 reports of suspected adverse reactions in 2025; 'på baggrund af de indberetninger, der er modtaget i 2025, er der ikke identificeret sikkerhedssignaler vedrørende cannabisslutprodukter'; redeemed prescriptions +64% and users +54% versus 2024. The 2024 report (25.11.2025) had likewise 3 reports (1 serious) and consumption +20%. Absolute 2025 figures are not in the news item; the ministry's press release of 28.11.2024 gave ca. 1,800 patients a year and 20,000 prescriptions since 2018. Quarterly statistics live on esundhed.dk (Sundhedsdatastyrelsen).

Source: Lægemiddelstyrelsen — Indberettede formodede bivirkninger ved medicinsk cannabis under forsøgsordningen i 2025 (11.09.2026) · read 1 October 2026